Sirio Pharma Co., Ltd. (SHE:300791)
China flag China · Delayed Price · Currency is CNY
16.93
+0.19 (1.14%)
Oct 28, 2026, 10:54 AM CST

Sirio Pharma Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
874.69595.14636.03534.491,502715.54
Short-Term Investments
0.9898.225.1720109.26-
Trading Asset Securities
115.055115.2200.6679.13530.77
Cash & Short-Term Investments
990.73698.34776.4755.141,6901,246
Cash Growth
63.65%-10.05%2.81%-55.32%35.60%80.57%
Accounts Receivable
789.41691.26702.53652.86476.96372.33
Other Receivables
15.3711.5820.814.994.454.27
Receivables
804.78702.84723.34657.85481.41376.6
Inventory
606.72458.24481.66481.06232.58239.61
Other Current Assets
129.6662.841.5438.8728.5851.99
Total Current Assets
2,5321,9222,0231,9332,4331,915
Property, Plant & Equipment
2,1562,1922,0931,9131,3321,173
Long-Term Investments
132.14166.5752.4494.11-337.79
Goodwill
403.33427.11417.1420.73163.05158.59
Other Intangible Assets
443.44459.89525.92544.84178.33160.75
Long-Term Deferred Tax Assets
134.57147.1281.3632.4813.7516.31
Long-Term Deferred Charges
219207.61258.14201.9259.4553
Other Long-Term Assets
41.2268.5234.6655.997.146.57
Total Assets
6,0625,5915,4865,1964,1863,820

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
573.42438.96393.43398.13259.25195.71
Accrued Expenses
81.9190.08191.85104.39152.3379.6
Short-Term Debt
310.26118.6854.82-0.160.12
Current Portion of Long-Term Debt
1,17597.0240.5921.25--
Current Portion of Leases
-23.3727.0942.87.265.19
Current Income Taxes Payable
38.0835.3348.0711.3911.0310.18
Current Unearned Revenue
45.5343.3236.9253.1325.8328.22
Other Current Liabilities
166.37113.3531.76120.0413.8413.43
Total Current Liabilities
2,3911,060824.54751.13469.69332.44
Long-Term Debt
262.721,1371,1561,049908.36852.28
Long-Term Leases
214.82307.41328.39256.1621.1416.68
Long-Term Unearned Revenue
92.8798.1759.765.6862.461.48
Long-Term Deferred Tax Liabilities
23.6826.7515.1528.0822.6912.44
Other Long-Term Liabilities
-1.76461.44479.470.01-
Total Liabilities
2,9852,6312,8452,6301,4841,275

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
308.06307.63235.87181.56180.5180.17
Additional Paid-In Capital
915.05905.92500.7547.51,0481,045
Retained Earnings
1,7971,6071,6231,4961,2781,138
Treasury Stock
-64.86-69.22-54.31-44.53--
Comprehensive Income & Other
131.7191.3200.88209.37195.13181.35
Total Common Equity
3,0872,9422,5062,3902,7022,545
Minority Interest
-10.4717.06135.36176.14-0.01
Shareholders' Equity
3,0772,9592,6412,5662,7022,545
Total Liabilities & Equity
6,0625,5915,4865,1964,1863,820

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
1,9631,6841,6071,369936.9874.26
Net Cash (Debt)
-972.47-985.26-830.1-614.1753.08372.05
Net Cash Growth
----102.42%-43.24%
Net Cash Per Share
-3.23-3.22-2.73-2.022.451.16
Filing Date Shares Outstanding
297.16306.19306.79304.67305.04304.49
Total Common Shares Outstanding
297.16306.19304.96304.67305.04304.49
Working Capital
140.92862.11,1981,1821,9631,582
Book Value Per Share
10.399.618.227.848.868.36
Tangible Book Value
2,2402,0551,5631,4242,3602,225
Tangible Book Value Per Share
7.546.715.124.687.747.31
Buildings
-1,3221,0671,000890.28528.67
Machinery
-1,5501,3901,242974.19773.89
Construction In Progress
-168.85238.4186.9469.28365.12